Reintegrating a Systematic Review Consultation With the General Practitioner After the Cancer Diagnosis Has Been Announced Into the Complex Cancer Patient Pathway: Feasibility Study
Launched by INSTITUT CLAUDIUS REGAUD · Sep 5, 2024
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how helpful it can be for cancer patients to have a follow-up meeting with their general practitioner (GP) after they receive their cancer diagnosis. The goal is to see if having this additional consultation can improve the support and care provided to patients with solid tumors, which are growths that can occur in various organs of the body. A total of 171 patients will be involved in the study, and each participant will be monitored for six months.
To participate, patients need to be at least 18 years old, have a confirmed diagnosis of a solid tumor, and be receiving treatment at one of the participating centers. They should also have a registered GP in the Occitanie region of France and be part of the French Social Security system. Those who are pregnant, breastfeeding, or involved in another clinical trial cannot join this study. Participants can expect to have their experiences and needs better addressed through this additional GP consultation, which aims to enhance their overall care during a challenging time.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age ≥ 18 years.
- • 2. Patient with a solid tumour whatever the organ.
- • 3. Patient treated in one of the participating centres as part of a system for announcing the diagnosis of a solid cancer.
- • 4. Patient undergoing cancer treatment in one of the participating centres.
- • 5. Patient with a registered general practitioner in the Occitanie region.
- • 6. Patient affiliated to a French Social Security scheme.
- • 7. Patient having signed informed consent prior to inclusion in the study and prior to any specific procedure for the study.
- Exclusion Criteria:
- • 1. Patient already included in another clinical trial concerning a care pathway.
- • 2. Patient deprived of liberty or under legal protection (curatorship and guardianship, safeguard of justice).
- • 3. Pregnant or breast-feeding woman.
About Institut Claudius Regaud
Institut Claudius Regaud is a leading cancer research and treatment center based in Toulouse, France, renowned for its commitment to advancing oncology through innovative clinical trials and multidisciplinary approaches. As a prominent sponsor of clinical research, the institute focuses on developing and evaluating cutting-edge therapies, enhancing patient care, and improving outcomes in cancer treatment. With a strong emphasis on collaboration and scientific excellence, Institut Claudius Regaud brings together a team of expert researchers, oncologists, and healthcare professionals dedicated to translating laboratory discoveries into effective clinical applications, thereby contributing significantly to the global fight against cancer.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Auch, , France
Toulouse, , France
Toulouse, , France
Toulouse, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported